Peyronie’s disease treatment market seen reaching $1.73 billion by 2030

The Peyronie’s disease treatment market is projected to grow from $1.05 billion in 2025 to $1.73 billion by 2030, driven by higher awareness, expanding urology care and demand for less invasive options. North America led the market in 2025, while Asia-Pacific is forecast to grow fastest.

Why it matters: - The market is expanding as more patients seek care for Peyronie’s disease and related erectile dysfunction. - Growth in non-surgical options and specialist access could broaden treatment use beyond severe cases that historically relied on surgery. - The market’s projected 10.5% CAGR through 2030 signals sustained demand for therapies, devices and procedures tied to men’s sexual health.

What happened: - The Business Research Company released its Peyronie’s Disease Treatment Market Report 2026, covering global market size, trends and forecasts through 2035. - The report estimates the market will rise from $1.05 billion in 2025 to $1.16 billion in 2026. - The report projects the market will reach $1.73 billion by 2030. - The company forecasts a 10.3% CAGR for 2025 to 2026 and a 10.5% CAGR for the longer-term outlook to 2030. - A free sample of the market report is available. - A full version of the market report is also available.

The details: - Peyronie’s disease treatment includes medicines, surgery and non-surgical therapies aimed at reducing plaque, improving curvature, easing pain and restoring sexual function. - Reported growth drivers include higher disease incidence, more erectile dysfunction cases, broader awareness of male sexual health disorders and wider access to specialized urology care. - Limited availability of early-stage non-surgical treatments has also supported demand for other approaches. - The report points to innovative antifibrotic drugs and biologic therapies as major future growth drivers. - Demand is rising for outpatient and non-invasive treatments. - Clinical research is advancing on regenerative medicine for penile tissue repair. - Combination therapy use is increasing. - Reimbursement policies supporting men’s health treatments are expected to help adoption. - Expected product and procedure trends include oral pharmacological therapies, collagenase injections, penile traction devices, low-intensity shockwave therapy and minimally invasive surgery combined with multimodal treatment approaches. - In 2025, North America was the largest market. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The market outlook suggests a shift from treating advanced disease with surgery toward broader use of earlier, less invasive interventions. - The emphasis on regenerative medicine and biologic therapies points to a pipeline that could change how Peyronie’s disease is managed if clinical results hold up. - Men’s health awareness is becoming a commercial driver, not just a public health theme. - The report cites UK data showing more than 2.74 million people visited sexual health clinics in England in 2023, with men making up more than 60% of new sexually transmitted infection diagnoses, underscoring rising engagement with sexual health services.

What’s next: - Market growth is expected to continue through 2030 as new therapies move through development and clinical adoption. - Broader reimbursement and improved healthcare access could accelerate uptake of specialty treatments. - Regional growth will likely be led by Asia-Pacific as access and awareness expand. - The company is offering expert contact support for readers seeking more information on the report.

The bottom line: - Peyronie’s disease treatment is moving from a niche surgical market into a broader men’s health category with steady global growth and a stronger focus on minimally invasive care.